Related references
Note: Only part of the references are listed.PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells
Hyo Jin Park et al.
JOURNAL OF IMMUNOLOGY (2015)
Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction
M. De Santis et al.
LUPUS (2015)
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
Iris Chiara Salaroglio et al.
ONCOTARGET (2015)
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol
Eriko Sumi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2014)
The anti-tumour effects of zoledronic acid
Jamal Zekri et al.
JOURNAL OF BONE ONCOLOGY (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer
M. Gallo et al.
ANNALS OF ONCOLOGY (2012)
Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes
Hisashi Ohnuki et al.
ARCHIVES OF ORAL BIOLOGY (2012)
A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy
James B. Canavan et al.
BLOOD (2012)
Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients
Fangfang Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Andrea Facciabene et al.
CANCER RESEARCH (2012)
Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer
Audrey Thomas-Schoemann et al.
JOURNAL OF IMMUNOLOGY (2012)
Regulatory T-Cells: Diverse Phenotypes Integral to Immune Homeostasis and Suppression
Richard A. Peterson
TOXICOLOGIC PATHOLOGY (2012)
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells
Barbara Castella et al.
JOURNAL OF IMMUNOLOGY (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
Wei Tan et al.
NATURE (2011)
Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis
Keiichiro Kimachi et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2011)
TLR7 and TLR8 Gene Variations and Susceptibility to Hepatitis C Virus Infection
Chiou-Huey Wang et al.
PLOS ONE (2011)
Cell-Based Immunotherapy With Mesenchymal Stem Cells Cures Bisphosphonate-Related Osteonecrosis of the Jaw-like Disease in Mice
Takashi Kikuiri et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
Michael Gobert et al.
CANCER RESEARCH (2009)
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
Adam M. Brufsky et al.
CLINICAL BREAST CANCER (2009)
Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity
Zuqiang Liu et al.
JOURNAL OF IMMUNOLOGY (2009)
RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4+CD25+ Regulatory T Cells in Chronic Colitis
Teruji Totsuka et al.
JOURNAL OF IMMUNOLOGY (2009)
Anti-Angiogenic Property of Zoledronic Acid by Inhibition of Endothelial Progenitor Cell Differentiation
Jun Yamada et al.
JOURNAL OF SURGICAL RESEARCH (2009)
The Treg/Th17 Cell Balance: A New Paradigm for Autoimmunity
Eli M. Eisenstein et al.
PEDIATRIC RESEARCH (2009)
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
Michael A. Morse et al.
BLOOD (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy
Justin T. Jordan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status
B. Ory et al.
MOLECULAR PHARMACOLOGY (2007)
Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo
Simon Read et al.
JOURNAL OF IMMUNOLOGY (2006)
Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms
Ming O. Li et al.
IMMUNITY (2006)
FOXP3 controls regulatory T cell function through cooperation with NFAT
Yongqing Wu et al.
CELL (2006)
Regulatory T-cell compartmentalization and trafficking
Shuang Wei et al.
BLOOD (2006)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy
K Sato et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals
LH Zou et al.
CANCER RESEARCH (2004)
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)
BQ Pan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies -: Possible involvement of regulatory T cells in disease progression
T Sasada et al.
CANCER (2003)
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
SP Jagdev et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
